Related Articles for PubMed (Select 12605726)

Current pharmacologic options for patients with Alzheimer's disease.

Reichman WE.

Ann Gen Hosp Psychiatry. 2003 Jan 29;2(1):1.

PMID: 12605726 [PubMed - as supplied by publisher]

Related Articles Free article in PMC

Cholinesterase inhibitors for Alzheimer's disease.

Birks J.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593. Review.

PMID: 16437532 [PubMed - indexed for MEDLINE]

Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.

Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, Waugh N.

Health Technol Assess. 2001;5(1):1-137. Review.

PMID: 11262420 [PubMed - indexed for MEDLINE]

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.

Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, Clegg A.

Health Technol Assess. 2006 Jan;10(1):iii-iv, ix-xi, 1-160. Review.

PMID: 16409879 [PubMed - indexed for MEDLINE]

Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.

Wilkinson DG, Francis PT, Schwam E, Payne-Parrish J.

Drugs Aging. 2004;21(7):453-78. Review.

PMID: 15132713 [PubMed - indexed for MEDLINE]

Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.

Nordberg A, Svensson AL.

Drug Saf. 1998 Dec;19(6):465-80. Review. Erratum in: Drug Saf 1999 Feb;20(2):146.

PMID: 9880090 [PubMed - indexed for MEDLINE]

Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.

Wolfson C, Oremus M, Shukla V, Momoli F, Demers L, Perrault A, Moride Y.

Clin Ther. 2002 Jun;24(6):862-86; discussion 837. Review.

PMID: 12117079 [PubMed - indexed for MEDLINE]

Pharmacologic treatments of dementia.

Bonner LT, Peskind ER.

Med Clin North Am. 2002 May;86(3):657-74. Review.

PMID: 12171061 [PubMed - indexed for MEDLINE]

The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial.

Raskind MA, Peskind ER, Truyen L, Kershaw P, Damaraju CV.

Arch Neurol. 2004 Feb;61(2):252-6.

PMID: 14967774 [PubMed - indexed for MEDLINE]

10:

Galantamine for Alzheimer's disease and mild cognitive impairment.

Loy C, Schneider L.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD001747. Review.

PMID: 16437436 [PubMed - indexed for MEDLINE]

11:

Acetylcholinesterase inhibitors and sleep architecture in patients with Alzheimer's disease.

Cooke JR, Loredo JS, Liu L, Marler M, Corey-Bloom J, Fiorentino L, Harrison T, Ancoli-Israel S.

Drugs Aging. 2006;23(6):503-11.

PMID: 16872233 [PubMed - indexed for MEDLINE]

12:

Realistic expectations for treatment success in Alzheimer's disease.

Geldmacher DS, Frolich L, Doody RS, Erkinjuntti T, Vellas B, Jones RW, Banerjee S, Lin P, Sano M.

J Nutr Health Aging. 2006 Sep-Oct;10(5):417-29. Review.

PMID: 17066215 [PubMed - indexed for MEDLINE]

13:

Current pharmacotherapies for Alzheimer's disease.

Knopman DS.

Geriatrics. 1998 Sep;53 Suppl 1:S31-4. Review.

PMID: 9745634 [PubMed - indexed for MEDLINE]

14:

Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology.

Touchon J, Bergman H, Bullock R, Rapatz G, Nagel J, Lane R.

Curr Med Res Opin. 2006 Jan;22(1):49-59. Erratum in: Curr Med Res Opin. 2006 Aug;22(8):1451.

PMID: 16393430 [PubMed - indexed for MEDLINE]

15:

Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease.

Krall WJ, Sramek JJ, Cutler NR.

Ann Pharmacother. 1999 Apr;33(4):441-50. Review.

PMID: 10332536 [PubMed - indexed for MEDLINE]

16:

The ABC of Alzheimer's disease: behavioral symptoms and their treatment.

Grossberg GT.

Int Psychogeriatr. 2002;14 Suppl 1:27-49. Review.

PMID: 12636179 [PubMed - indexed for MEDLINE]

17:

The clinical efficacy and safety of galantamine in the treatment of Alzheimer's disease.

Dengiz AN, Kershaw P.

CNS Spectr. 2004 May;9(5):377-92.

PMID: 15115951 [PubMed - indexed for MEDLINE]

18:

Galantamine: a review of its use in Alzheimer's disease.

Scott LJ, Goa KL.

Drugs. 2000 Nov;60(5):1095-122. Review.

PMID: 11129124 [PubMed - indexed for MEDLINE]

19:

A prospective, double-blind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population.

Suh GH, Yeon Jung H, Uk Lee C, Hoon Oh B, Nam Bae J, Jung HY, Ju YS, Kil Yeon B, Park J, Hong I, Choi S, Ho Lee J; Korean Galantamine Study Group.

Clin Ther. 2004 Oct;26(10):1608-18.

PMID: 15598477 [PubMed - indexed for MEDLINE]

20:

Long-term treatment of Alzheimer disease: efficacy and safety of acetylcholinesterase inhibitors.

Winblad B, Jelic V.

Alzheimer Dis Assoc Disord. 2004 Apr-Jun;18 Suppl 1:S2-8. Review.

PMID: 15249842 [PubMed - indexed for MEDLINE]

Recent Activity